| Hazard Information | Back Directory | [Description]
Zifaxaban, also known as TY-602, is a factor Xa inhibitor potentially for the treatment of thrombosis. | [Uses]
Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC50 of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research[1]. | [in vivo]
In venous thrombosis models in rats, Zifaxaban strongly suppresses thrombus formation with ED50 values of 3.09 mg/kg, and its best efficacy time occurred at 2 h after administration[1].
In arteriovenous-shunt thrombosis and carotid thrombosis models in rats, Zifaxaban inhibits thrombus formation in a dose-dependent manner[1].
| [References]
[1] Qiu X, et al. Pre-clinical pharmacodynamic study of a novel oral factor Xa inhibitor zifaxaban. Eur J Pharmacol. 2018 Oct 5;836:50-56. DOI:10.1016/j.ejphar.2018.08.019 |
|
|